Abuse Reduction Claim In Opioid Label Will Be Difficult To Attain
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA draft guidance says there is no clear epidemiologic strategy for gathering the data to demonstrate that has reduced abuse; the agency outlines four possible kinds of abuse deterrence claims, three of which can be obtained through pre-market studies.
You may also be interested in...
Abuse-Deterrent Opioids: FDA Regulatory Options Aired At Meeting
Brand industry favors two- to three-year period for withdrawal or reformulation of products without abuse-deterrent features, while generic industry calls for expedited review pathway. Purdue and Zogenix agree to waive three-year market exclusivity for their respective hydrocodone products.
Abuse-Deterrent Opioids: FDA Regulatory Options Aired At Meeting
Brand industry favors two- to three-year period for withdrawal or reformulation of products without abuse-deterrent features, while generic industry calls for expedited review pathway. Purdue and Zogenix agree to waive three-year market exclusivity for their respective hydrocodone products.
Abuse-Deterrent Opioid Claims Need Studies, Studies And More Studies
FDA’s review of Purdue’s Targiniq ER, one of only two opioids with approved abuse-deterrent claims, shows that the agency’s skepticism about the state of the technology to deter opioid abuse can be overcome – by an exhaustive set of comparisons in clinical, in vitro and PK studies.